Eleven Therapeutics News
6 articles
growth-positive
Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer
Eleven Therapeutics, a biotechnology company specializing in mRNA therapeutics, has appointed Dr. Paloma H Giangrande as its Chief Technology Officer (CTO). Dr. Giangrande is a leader in the field of nucleic acid therapeutics and has held key leadership roles at renowned biotechnology companies, including Moderna and Wave Life Sciences. In her new role, she will drive the strategic direction for Eleven Therapeutics core xRNA technologies and platforms. The companys CEO, Prof. Yaniv Erlich, expressed his enthusiasm about Dr. Giangrande joining the team, stating that her appointment represents a strategic milestone for the company.
Management Changes
growth-positive
Dong-A ST Signs R&D Agreement with Eleven Therapeutics for RNA-based Gene Therapy
South Korean pharmaceutical company Dong-A ST has signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The partnership will focus on discovering RNA therapies for fibrotic diseases using Eleven Therapeutics TERA platform technology, which uses AI and machine learning to decode high-throughput RNA chemical modifications. This collaboration aligns with Dong-A STs strategy of expanding its R&D capabilities in the field of gene therapy.
PartnersExpand
growth-positive
Eleven and Novo Nordisk partner to develop nucleic acid therapeutics - Pharmaceutical Technology
Eleven Therapeutics and Novo Nordisk have announced a research partnership to identify novel nucleic acid molecules to treat cardiometabolic diseases using Eleven’s DELiveri platform. The DELiveri platform uses AI and machine learning in combination with DNA-encoded libraries to find conjugates that can transport therapeutic molecules. Novo Nordisk will have exclusive rights to specific cell types and applications developed using the DELiveri platform. This partnership is part of a series of investments made by Novo Nordisk, including an expansion of its manufacturing facilities in Denmark and a partnership with Aspect Biosystems.
PartnersInvestment
Growth-Positive
"We are revolutionizing the world of RNA" | CTech
Yaniv Erlich, CEO of Eleven Therapeutics, spoke at the Mind the Tech conference in London, stating that his company is revolutionizing the world of RNA. The conference, which is an annual event by Calcalist, focused on the changes experienced by the high-tech sector over the past year. It assessed the impact of market shakeups on the high-tech economy and reviewed upcoming trends in the technology world.
growth-positive
Eleven Therapeutics Raises $22M in Seed Funding - FinSMEs
Eleven Therapeutics, a biotechnology company focused on advancing nucleic acid therapeutics, has raised $22 million in seed funding. The funding includes a $9 million commitment from the Bill and Melinda Gates Foundation, with $5 million towards future equity investment and $4 million as a non-dilutive grant. The funding will support the development of a platform that designs small interfering RNAs (siRNAs) with ultra-long durability. Eleven Therapeutics aims to develop siRNA treatments for respiratory diseases using its flagship invention, SCSI-RNA™. The company has collaborative hubs in Cambridge, UK; Boston, US; and Tel Aviv, Israel. The funding will also promote wide accessibility of Elevens treatments to people in need in developing countries.
Investment
growth-positive
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools BioSpace
Twist Bioscience and Eleven Therapeutics have developed a replicon tool for studying viral genome replication and antiviral drug screening, as well as vaccine and therapeutic development. The replicon is a synthetic viral RNA molecule that mimics viruses but has been engineered to remove the infectious portion of the genome. The teams demonstrated the development of a safe and efficient SARS-CoV-2 replicon-generating engine. The replicon can be used to study viral activity without the need for patient samples or handling live virus. The replicon system is flexible and can be used to produce other variants of the virus. Twist Bioscience and Eleven Therapeutics are leveraging synthetic biology to complement efforts in developing therapies and interventions for future variants of concern.
CustomersPartners
